Working together to fight the epidemic | Gentech won the honorary title of high-quality partner in the second phase of production expansion project of COVID-19 inactivated vaccine
On May 31, the commissioning ceremony of the second phase production expansion project of COVID-19 Inactivated Vaccine of Sinopharm China Biological Wuhan Institute of Biological Products was successfully held in Wuhan. The production expansion project was launched on March 5, and will be completed and put into production in only 86 days. It is estimated that the production and supply of 600 million doses of COVID-19 vaccine will be realized within the year, and the design plan of annual production capacity of 1 billion doses will be realized in the future. At the commissioning ceremony, Zhengfan Technology was awarded the honorary title of "Working Together to Fight the Epidemic" by Sinopharm China Biotech Wuhan Institute of Biological Products as a high-quality partner in the second phase of production expansion project of COVID-19 inactivated vaccine.
At the launch ceremony, Liu Jingzhen, chairman of Sinopharm Group, said in his speech that the Phase II production expansion project of COVID-19 Inactivated Vaccine of Wuhan Institute of Biological Products only took less than three months to complete the construction and meet the production conditions. This is another major victory for China National Pharmaceutical Group and the people of Hubei, another major achievement for the central and local governments to join hands in the fight against the epidemic, and another major action for the heroic city of Wuhan to support the global fight against the epidemic.
The rapid implementation of this expansion project cannot be achieved without the strong cooperation of various design units, participating units, equipment units, and equipment suppliers. It is through the efforts of all parties to work overtime that the goal of substantially increasing the annual production capacity of COVID-19 Vaccine in China has been achieved, which has made a significant and solid step forward in the accessibility and affordability of COVID-19 Vaccine for people in Hubei, the whole country and even the world. As a member of the expansion project, Zhengfan Technology feels honored.
The Phase II production expansion project of COVID-19 inactivated vaccine is the key project of Zhengfan Technology's 2021 annual development plan. Since winning the bid on April 12, Zhengfan Technology has responded quickly, entered the "wartime" state immediately, and fully played the service spirit of "people first, customer first, service oriented, demand oriented", and completed the technical improvement and equipment delivery in a very short time.
Water quality, as the most critical link in vaccine production, will directly affect the quality of subsequent vaccines and the overall progress of production expansion. As a supplier of complete sets of pharmaceutical water equipment for China's first COVID-19 vaccine project entering the clinical stage, Zhengfan Technology comprehensively sorted out the key points and difficulties of the project. Under the unified command of the leadership team, it coordinated high-quality forces, guaranteed time, quality and quantity. Wusheng Institute provided system planning and design, system construction, GMP verification and operation services, including equipment manufacturing, system installation and commissioning, and GEP project management, to meet the stringent requirements of biopharmaceutical customers for ultra-high water quality, high stability, and compliance, and contributed its own strength to the R&D and listing of COVID-19 vaccine.
Since the outbreak of the COVID-19 epidemic, Zhengfan Technology has always taken social responsibility as its own responsibility and stuck to the forefront of the fight against the epidemic. In addition to participating in the second phase of the production expansion project of COVID-19 inactivated vaccine, Zhengfan Technology has also actively participated in international anti epidemic activities. In March this year, Zhengfan Technology overcame the severe challenges of the current international epidemic, selected elite teams and rushed to Bangladesh to implement the Renata and IBN SINA two pharmaceutical factory projects. They represent Zhengfan Technology and also represent the confidence of the motherland. With responsibility and responsibility, they show the image of a major country and demonstrate the spirit of mutual assistance of the "the Belt and Road".
